Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

American Heart Association Honors Centre for Neuro Skills with Group Stroke Hero Award

Centre for Neuro Skills

American Heart Association (AHA) awarded Centre for Neuro Skills, a leading brain injury and rehabilitation provider, with the Group Stroke Heroes award. The group hero award recognizes a group committed to educating, inspiring, and bringing awareness to stroke. CNS was selected among other stroke support groups, stroke teams, families, private associations, medical facilities and more. CNS’ mission is to provide quality post-acute neurorehabilitation to stroke and traumatic brain injury survivors, helping them to regain their independence. Its group of physicians, researchers, clinicians, and therapists deliver innovative therapy treatment to stroke patients to reduce disability and maximize independence. CNS regularly partners with organizations like AHA and the Brain Injury Association of America to raise funds, awareness, and education for stroke prevention and rehabilitation. In 2023, CNS raised more than $26,000 for innovative research and education to fight against heart disease and stroke through the participation of four American Heart Association Heart Walks in Dallas, Tarrant County, Kern County, and Austin. CNS President and Chief Executive Officer David Harrington chaired the Kern County Heart Walk, while Dr. Matthew Ashley, Chief Medical Officer, joined the Executive Leadership Team in Austin County. Clinicians and staff across all seven CNS locations hosted fundraisers, silent auctions, and events - all geared toward raising money for the Heart Walks. “We at Centre for Neuro Skills are all so proud and honored to be recognized with the Group Stroke Hero Award by the American Heart Association,” said David Harrington, president and chief executive officer of Centre for Neuro Skills. “I want to thank our entire CNS team for their tireless dedication to helping our stroke patients receive the best possible rehabilitation therapy.” In addition to community involvement, CNS’ experts educate the public about stroke through CNS’ media platforms, website, continuing education webinars, contributed content and media interviews. CNS regularly invites stroke survivors to share their stories through their online blog and YouTube channel, showcasing the different types of strokes, the causes of strokes, and their journeys to recovery. AHA also selected one of CNS’ patients, Craig Northcutt, who received the Stroke Survivor Hero award, recognizing an individual who has survived a stroke and used their experience to educate, inspire and bring awareness about stroke. To learn more about Centre for Neuro Skills (CNS) and its brain injury rehabilitation programming, visit www.neuroskills.com. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

May 01, 2024 10:10 AM Pacific Daylight Time

Image

TOWER CAPITAL GROUP SPONSORS A GLOBAL INVESTMENT CONSORTIUM

TOWER CAPITAL GROUP

TOWER CAPITAL GROUP, market maker of Generational Health, defines the trillion dollar category as pivotal to evolutionary capacity, country competitiveness, and global health. In a recent publication TOWER reveals that a critical lever for Generational Health is Women’s Health. TOWER states that funding women’s health innovation is a requirement for Generational Health and has committed to support this effort at a global scale. In demonstration of this commitment, TOWER expands its relationship with the Centre for Health and Healthcare at The World Economic Forum, and is the lead champion and sponsor of a first-in-kind global women’s health investment consortium. The Consortium, ”Global Women’s Health Responsible Investment Consortium” is designed to serve the global need for innovation in women’s health. Not only to be a channel of investment, but responsible and sustainable funding for the category. The Consortium serves to: Unite Global Investors with Global Innovators for Women’s Health Outcomes Accelerate and Measure Commitments to Funding and Secure Matching Commitment to select Innovators Leverage The World Economic Forum and Global Alliance for Women’s Health Platform to Curate Investment Outcomes Amplify Tower Capital’s Collective of ~1000+ Innovators Open the Aperture of Women’s Health Through the Lens of Generational Health “There is nothing more important than actualizing innovation and scientific breakthroughs for women, to ensure Generational Health.” Sanskriti Thakur, TOWER CAPITAL GROUP Founder and Chairwoman. “In collaboration with TOWER CAPITAL, we are delighted to launch the First Global Responsible Investment Consortium for Women’s Health. Together, let’s bridge the funding gap and unlock innovation for better health outcomes for all women.“ Shyam Bishen, Head, Centre for Health & Healthcare, The World Economic Forum. About TOWER: Operating across industries, regions and partners, TOWER CAPITAL GROUP and its affiliates deploy expertise and capital to uncover economic value, investment, and innovation within Generational Health and bring it to stakeholders across the globe. Generational Health are those effects passed on genetically, epigenetically, and environmentally, shaping humanity’s evolutionary curve. It represents a multi-trillion-dollar opportunity encompassing critical areas of community, environment, and women’s health. Visit www.towercapital.org for more information on Generational Health, the company, and its mission. Investor Inquiries: Sheri Bailey sheri@towercapital.org Contact Details For Media Inquiries please contact TOWER CAPITAL GROUP contact@towercapital.org Company Website https://towercapital.org/

May 01, 2024 12:00 PM Eastern Daylight Time

CEO Roby Zomer discusses Argent BioPharma's future in pharmaceuticals

Argent BioPharma Ltd

Argent BioPharma managing director and CEO Roby Zomer speaks to Proactive's Stephen Gunnion following the company's rebranding from MGC Pharmaceuticals, alongside a comprehensive restructuring. Zomer explained the shift marks a refined focus on the pharmaceutical sector, discarding previous activities not aligned with pure pharmaceutical processes. Zomer highlighted the company’s advancement in drug discovery, particularly through a multidisciplinary approach and modern technologies such as nanotechnology and mRNA modulation. These innovations are targeted at addressing unmet medical needs. The company has developed notable products including CannEpil and CimetrA. CannEpil targets refractory epilepsy and has shown efficacy in controlling seizures without reported adverse events. CimetrA, developed during the COVID-19 pandemic, is designed to alleviate COVID-19 symptoms and prevent cytokine storms, with potential applications in treating other autoimmune diseases. Both drugs are now being prescribed in key markets including the United States and Europe. Zomer expressed optimism about the future, emphasizing ongoing research and progress in obtaining regulatory approvals. The focus will remain on enhancing early patient access schemes, which are expected to significantly impact revenue. Over the next 24 months, Argent BioPharma plans to introduce more innovative treatments to the market. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

May 01, 2024 10:07 AM Eastern Daylight Time

Video

Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal

Immunic Inc

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) in the peer-reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology. Vitt noted that the EMPhASIS trial demonstrated a notable reduction in gadolinium-enhancing lesions by 78% and 74% in two high-dose groups compared with the placebo. These results also correlate with improvements in serum neurofilament light chain levels, consistent with recent interim phase 2 clinical data from the ongoing CALLIPER trial in progressive MS, indicating ongoing progress in the field. Vitt highlighted the study's contribution to understanding the neuroprotective and anti-inflammatory effects of the treatment under investigation. The drug's potential impact on the treatment landscape of MS, particularly its role in addressing disease progression independent of relapse activity, was emphasized. Immunic is also conducting the CALLIPER trial in progressive MS, with key results expected by April 2025. Additionally, the phase 3 ENSURE trials are actively enrolling, with projected readouts in 2026. Dr Vitt expressed optimism about the drug's unique profile, combining safety and effectiveness in potentially altering the management of all forms of MS. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 01, 2024 10:02 AM Eastern Daylight Time

Video

Poolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drug

Poolbeg Pharma PLC

Poolbeg Pharma PLC CEO Jeremy Skillington and Tim Coté CEO of Silk Road Therapeutics join Proactive's Stephen Gunnion with details of an exclusive 12-month option agreement with Silk Road Therapeutics for Poolbeg to acquire a novel topical drug aimed at treating oral ulcers in patients with Behçet's disease, a rare and debilitating condition. Skillington said the move is aligned with Poolbeg's strategic focus on rare and orphan diseases. Coté, with an extensive background in orphan drug approvals from his time at the FDA, highlighted the potential of the drug given its unique formulation and unmet need in the market. He explained the severe impact of Behçet's disease, underscoring the innovative potential of their topical treatment in improving the quality of life for those affected. Both CEO expressed optimism about their collaboration's potential to fast-track this novel treatment to market, leveraging Poolbeg’s and Silk Road's combined expertise. Furthermore, Skillington provided insights into Poolbeg’s financial health and strategic developments over the past year, mentioning a robust cash position of £12.2 million at the end of 2023. He emphasised the company's disciplined capital allocation and the expansion of its intellectual property portfolio. Looking ahead, Skillington outlined Poolbeg's focus on progressing its pipeline, particularly ongoing projects like POLB001 in the oncology sector, addressing cytokine release syndrome—a critical side effect in cancer immunotherapies. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 01, 2024 09:51 AM Eastern Daylight Time

Video

Nevis Brands Expands Major Distribution with Exclusive Licensing Agreement in Mississippi

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to announce the company has announced a significant expansion in Major's distribution through an exclusive licensing agreement with Stash House for production and distribution in Mississippi. Under this agreement, Stash House will have exclusive rights to produce and distribute the full lineup of Major products in the state. The Major lineup includes dose-able 100mg THC beverages available in flavors such as Blueberry, Fruit Punch, and Blackberry Lemonade. Known for delivering the effects of cannabis within a short timeframe of 10-20 minutes after consumption, Major has gained popularity since its initial launch in Washington State in 2019, with over 5 million bottles sold to date. Kueber highlighted Mississippi's recent legalization of cannabis for medical use in January 2023, which has led to the licensing of over 400 dispensaries in the state. This agreement marks Major's entry into its 10th state for production, further expanding its reach across the United States. Currently available in Washington, Oregon, Arizona, Ohio, Colorado, Nevada, California, and Missouri, Major is also preparing for production in Michigan, signaling the brand's continued growth and market penetration. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 30, 2024 12:12 PM Eastern Daylight Time

Video

Cloud DX Reports Significant Revenue and Profit Growth in 2023

Cloud DX

Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to discuss the company's impressive performance in its 2023 full-year results. Notably, Cloud DX reported a substantial 55.4% increase in revenue, reaching $1.8 million. A key driver of this growth was the remarkable surge in subscription revenue, which soared by nearly 70%, surpassing the overall revenue increase. This shift towards subscription revenue, characterized by high margins exceeding 90%, has significantly bolstered profitability, with gross profit doubling to $1.2 million, reflecting a remarkable 112% increase. The company's stellar performance is further underscored by its operational efficiency, as evidenced by a noteworthy $1.3 million reduction in operating expenses. This reduction was achieved through strategic staff cost management, executed without compromising on customer service quality. As a result, Cloud DX achieved a more than 20% decrease in operating loss, setting a positive trajectory towards profitability and positive cash flow in the coming quarters. Looking ahead, Cloud DX is well positioned to solidify its presence in the remote patient monitoring market in Canada. The company boasts the largest share of provincial contracts and maintains robust partnerships with major industry players such as Medtronic and Teladoc Health. Moreover, Cloud DX's successful early conversion of convertible debt at a premium underscores its strong financial management and commitment to enhancing shareholder value. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 30, 2024 12:04 PM Eastern Daylight Time

Video

Hemogenyx Pharmaceuticals outlines significant progress with HEMO-CAR-T in 2023

HemoGenyx Pharmaceuticals

Hemogenyx Pharmaceuticals PLC CEO Dr Vladislav Sandler tells Proactive's Stephen Gunnion that 2023 was a significant year for the company, marked by notable progress with its HEMO-CAR-T product candidate. The key achievement for the year was the submission of a new Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to commence a phase one clinical trial for the treatment of relapsed refractory acute myeloid leukemia. However, the process faced a setback due to issues with lentivirus purity, resulting in a clinical hold. After re-manufacturing the lentivirus, Hemogenyx successfully addressed the FDA's concerns and received approval to proceed with the clinical trials. Furthermore, Sandler reported a successful fundraising which will support the upcoming clinical studies. The company also entered a service agreement with Prevail Infoworks for the clinical trials. In addition to its advancements in HEMO-CAR-T, Hemogenyx continued developing other programs, such as its proprietary Chimeric Bait Receptor (CBR) platform, showing promise in treating non-Hodgkin lymphoma and exploring applications in solid rare tumors. For 2024, the primary focus remains on advancing these clinical trials, particularly the phase one studies, with an immediate goal to initiate patient treatment. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 29, 2024 11:52 AM Eastern Daylight Time

Video

Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role

Immunic Inc

Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion on the International Day of Immunology to discuss the broad and crucial role of immunology in human health. Vitt said immunology encompasses immune responses against pathogens like viruses, including the coronavirus, and also plays a significant role in combating cancer. He highlighted the importance of the immune system in managing and preventing autoimmune diseases, where the body mistakenly attacks its own cells, leading to various conditions. Focusing on Immunic's efforts, Vitt detailed their drug development pipeline, particularly in addressing chronic inflammatory and autoimmune diseases such as multiple sclerosis, ulcerative colitis, Crohn's disease, and celiac disease. He spotlighted multiple sclerosis, with ongoing phase three studies in its relapsing form and a phase two study, named the CALLIPER trial, for its progressive form. The latter holds particular promise as it targets an area with currently no available treatments. For celiac disease, Vitt reported promising results from a phase one B proof-of-concept study that showed positive data across various metrics, including histology and biomarker levels. Plans are underway for further phase two studies in celiac disease and potentially other indications. Vitt also shared his personal journey from chemistry to immunology, driven by the potential to develop drugs that address significant medical needs. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 29, 2024 11:11 AM Eastern Daylight Time

Video

1 2 3 4 5 ... 185